TG103
A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
CSPC Baike (Shandong) Biopharmaceutical Co · Phase 2 · Completed · Enrollment 314
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| TG103 7.5 mg | n/r | n/r | n/r | n/r | n/r |
| Placebo 7.5 mg | n/r | n/r | n/r | n/r | n/r |
| TG103 15 mg | n/r | n/r | n/r | n/r | n/r |
| Placebo 15 mg | n/r | n/r | n/r | n/r | n/r |
| TG103 22.5 mg | n/r | n/r | n/r | n/r | n/r |
| Placebo 22.5 mg | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.